or Try an Advanced Search...

    ETF Components for SBIO - ALPS Medical Breakthroughs ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    CORT B -0.30 3.66
    KRYS C 2.35 3.39
    RNA C -2.50 3.29
    ACLX C 0.00 3.19
    ALKS C -0.75 3.15
    CRNX C 1.71 2.95
    IMVT F 1.41 2.66
    DNLI D -0.82 2.36
    MRUS F 3.32 2.21
    AGIO C 1.68 2.05
    PTCT B 2.22 2.02
    XENE D 1.17 2.01
    VRNA B -2.55 1.98
    FOLD F -0.94 1.95
    EWTX C 0.09 1.92
    ACAD C -0.55 1.89
    VERA C 2.80 1.82
    ZLAB C -2.02 1.79
    VCEL B -0.96 1.73
    PTGX D 2.46 1.61
    CGON F 0.31 1.57
    IDYA F 4.15 1.53
    GERN D 0.75 1.48
    MIRM B -0.48 1.47
    KROS D -0.55 1.40
    LBPH A 0.00 1.40
    AKRO B 1.84 1.32
    MNKD C 0.29 1.26
    IRON B 1.53 1.21
    GLPG F -1.64 1.19
    TARS C -0.39 1.16
    IMCR D -0.93 1.07
    CLDX F -0.68 1.06
    ARVN F 10.67 1.06
    BCRX D 2.60 0.99
    XNCR B 1.60 0.98
    RCUS F -2.33 0.95
    NTLA F 5.18 0.94
    SNDX F -2.19 0.93
    SPRY C -1.25 0.88
    VRDN D -0.86 0.84
    KURA F -36.77 0.83
    DAWN D -2.06 0.82
    AUPH B 6.43 0.78
    PHVS C 2.63 0.76
    APLT C -1.70 0.72
    COGT D -1.10 0.69
    ETNB C 5.01 0.57
    LQDA F 0.30 0.54
    PLRX D 0.94 0.53
    PRTA F 0.28 0.52
    ERAS C -1.52 0.51
    REPL D -1.60 0.50
    IRWD F -5.11 0.44
    AVXL B 6.43 0.42
    ANNX F 0.19 0.40
    MLYS F -5.79 0.39
    ALT C 4.41 0.37
    OLMA F -4.95 0.37
    ANAB F 4.23 0.36
    FLGT F -1.91 0.35
    ALLO F 2.93 0.35
    CELC F -0.39 0.34
    YMAB F -4.17 0.34
    URGN F 0.87 0.34
    SVRA F 3.51 0.34
    FULC F -0.67 0.33
    TBPH B -3.61 0.32
    FDMT F -4.99 0.31
    GHRS C -12.15 0.31
    ARCT F 5.57 0.31
    AURA C 3.20 0.30
    ALEC F 3.44 0.28
    CMPS F -4.51 0.23
    ACIU D 1.54 0.22
    VNDA C 0.82 0.20
    ITOS F 3.57 0.19
    STRO F -5.24 0.17
    ALDX D 1.05 0.17
    ZNTL F 1.60 0.17
    ENTA F 2.53 0.14
    INZY F -3.58 0.12
    HLVX F 1.68 0.06

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Medicine Biotechnology Cancer Biology Clinical Medicine Life Sciences Organ Systems Disease Immunology Antibodies Autoimmune Disease Clinical Development Immune System Chemical Compounds Monoclonal Antibodies Neurological Disorders Rare Diseases Solid Tumors Alcohol
    Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Specialty & Generic Medical Care Facilities

    Recent News for ALPS Medical Breakthroughs ETF & its Holdings

    Date Stock Title
    Nov 21 ANAB AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
    Nov 21 IMVT Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?
    Nov 21 REPL Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
    Nov 21 ACAD Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
    Nov 21 GERN Geron: A Strong Launch And Financial Deals Make It Attractive
    Nov 21 KURA Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
    Nov 21 FDMT 4D Molecular initiated by Morgan Stanley at underweight
    Nov 21 KURA Analysts supportive of Kura/Kirin deal despite major selloff (update)
    Nov 21 GERN High Growth Tech Stocks to Watch in November 2024
    Nov 21 CORT 3 Reasons Growth Investors Will Love Corcept (CORT)
    Nov 21 KURA Kura Oncology: A Contender In The Field Of Precision Medicine
    Nov 21 KURA Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
    Nov 21 ALKS Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?
    Nov 21 KURA Kura Oncology partners Kyowa Kirin to advance AML treatment
    Nov 20 KURA Kura stock slides 17% on Kyowa Kirin deal for ziftomenib
    Nov 20 KURA Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
    Nov 20 DAWN Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
    Nov 20 SPRY ARS Pharmaceuticals: Demand Curve Is Key Unknown
    Nov 20 CORT Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet
    Nov 20 CLDX Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
    The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.
    Exchange Traded Fund ETF Index Fund Biotechnology Pharmaceutical Passive Management
    Back to the Main SBIO Page...